News

US FDA approves Gilead's twice-yearly injection for HIV prevention
The U.S. Food and Drug Administration on Wednesday approved Gilead Sciences lenacapavir, a twice-yearly injection, for ...
Long-acting HIV prevention drug from Gilead wins FDA approval. Will it get to the people who need it?
The drug is groundbreaking, potentially eliminating the need for a long-sought-after HIV vaccine. In her own words: Anne ...
Agence France-Presse on MSN2d
US approves Gilead's twice-yearly injection to prevent HIV
The US Food and Drug Administration on Wednesday approved Gilead Sciences' twice-yearly injection to prevent HIV -- a move ...
Gilead Sciences (NasdaqGS:GILD) Gains FDA Approval For Yeztugo As PrEP HIV Option
Gilead Sciences (NasdaqGS:GILD) recently achieved FDA approval for Yeztugo, a significant step in HIV prevention as the first ...
GlobalData on MSN1d
Gilead Sciences’ Yeztugo receives approval from US FDA for HIV
The US Food and Drug Administration (FDA) has approved Gilead Sciences' injectable product, Yeztugo (lenacapavir), as a ...
This twice-a-year shot to prevent HIV could stop transmission — if people can get it
The U.S. has approved the world’s only twice-a-year shot to prevent HIV, the first step in an anticipated global rollout that ...
FDA approves new twice-yearly HIV shot. What to know
The FDA approved Gilead's HIV prevention drug lenacapavir, a twice-a-year injectable medication that clinical trials show ...
FDA approves first twice-yearly injection that prevents HIV infection
The injectable HIV prevention treatment Yetzugo, made by Gilead Sciences, has received FDA approval, offering a twice-yearly alternative to daily medications.
Gilead Sciences: Strong Buy On Pipeline Momentum And Cost Discipline
Gilead Sciences shows strong Q1 execution, pipeline momentum, and margin upside, led by HIV and PrEP launches. See why GILD ...
Fierce Pharma2d
FDA signs off on Gilead's landmark long-acting PrEP med, signaling new era in HIV prevention
With the FDA’s much-anticipated nod for Gilead Sciences’ long-acting HIV pre-exposure prophylaxis (PrEP) injection Yeztugo ...
BioPharma Dive2d
FDA approves twice-yearly shot of Gilead drug for HIV prevention
The clearance ushers in a closely-watched launch for Gilead, which aims to show a long-acting injection can upend a market ...
Pharmabiz17h
Gilead Sciences’ Yeztugo receives nod; the first and only US FDA-approved HIV prevention option offering 6 months of protection
Gilead Sciences’ Yeztugo receives nod; the first and only US FDA-approved HIV prevention option offering 6 months of protection: Foster City, California Friday, June 20, 2025, 1 ...